CABA
CABA clinical trials: Cabaletta Bio, Inc.
Every trial on ClinicalTrials.gov where Cabaletta Bio, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CABA on the catalyst calendar · CABA registry changes
- Primary completion Jul 2028Sponsor estimatePhase 2/Phase 3NCT06154252RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory...Cabaletta Bio · Idiopathic Inflammatory MyopathyRecruitingCABALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2029Sponsor estimatePhase 1/Phase 2NCT06359041RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia GravisCabaletta Bio · Generalized Myasthenia Gravis (gMG)RecruitingCABALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2029Sponsor estimatePhase 2/Phase 3NCT06328777RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic...Cabaletta Bio · Systemic SclerosisRecruitingCABALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2029Sponsor estimatePhase 1/Phase 2NCT04422912A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells...Cabaletta Bio · Pemphigus VulgarisRecruitingCABALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimatePhase 1/Phase 2NCT06121297RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusCabaletta Bio · Systemic Lupus ErythematosusRecruitingCABALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 1/Phase 2NCT07006805RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple SclerosisCabaletta Bio · Relapsing Multiple Sclerosis (RMS)WithdrawnCABALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 24, 2025ActualPhase 1NCT05451212Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia GravisCabaletta Bio · MuSK Myasthenia GravisCompletedCABALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner